Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer.

Animals Caspase 3 Histone Deacetylase Inhibitors / pharmacology Histone Deacetylases / metabolism Humans Male Mice Pentanoic Acids Prostate Prostatic Neoplasms / drug therapy
Apoptosis Cancer stemness HDAC inhibitor Prostate cancer Valeric acid

Journal

Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512

Informations de publication

Date de publication:
29 Sep 2022
Historique:
received: 29 06 2022
accepted: 29 07 2022
entrez: 29 9 2022
pubmed: 30 9 2022
medline: 4 10 2022
Statut: epublish

Résumé

Prostate cancer is the second cause of cancer-related deaths in men worldwide, and new agents for curing the disease are still needed. In this study, we theoretically and experimentally demonstrated that valeric acid (VA) was a HDAC inhibitor, and anti-cancer efficacy of VA in prostate cancer cells was also observed using either 2D or 3D culture systems. VA was cytotoxic for prostate cancer cells but low toxic to normal cells. VA significantly inhibited E2F1/E2F3 expression but increased CASP3 activity. In vivo mouse models further showed its anti-cancer activity and potential property of chemosensitizer with promoting apoptosis. The findings suggest that VA acts as a HDAC3 inhibitor with anti-cancer effect on prostate cancer by regulating E2F1/E2F3/CASP3 axis.

Identifiants

DOI: 10.1007/s12032-022-01814-9 PMID: 36175803 PMC: PMC9522682
pubmed: 36175803
doi: 10.1007/s12032-022-01814-9
pii: 10.1007/s12032-022-01814-9
pmc: PMC9522682
doi:

Substances chimiques

Histone Deacetylase Inhibitors 0
Pentanoic Acids 0
Caspase 3 EC 3.4.22.-
Histone Deacetylases EC 3.5.1.98
histone deacetylase 3 EC 3.5.1.98
n-pentanoic acid GZK92PJM7B

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

213

Subventions

Organisme : Guangzhou Municipal Science and Technology Project
ID : 202102021125

Informations de copyright

© 2022. The Author(s).

Références

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
doi: 10.3322/caac.21492 pubmed: 30207593
Mantia C, Choudhury AD. Transdermal oestrogen for advanced prostate cancer. Lancet. 2021;397(10274):556–7.
doi: 10.1016/S0140-6736(21)00305-6 pubmed: 33581806
Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701–11.
doi: 10.1038/nrc4016 pubmed: 26563462 pmcid: 4771416
Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19–25.
doi: 10.1016/j.molonc.2007.01.001 pubmed: 19383284 pmcid: 5543853
Zhou Y, Peng J, Jiang S. Role of histone acetyltransferases and histone deacetylases in adipocyte differentiation and adipogenesis. Eur J Cell Biol. 2014;93(4):170–7.
doi: 10.1016/j.ejcb.2014.03.001 pubmed: 24810880
West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Investig. 2014;124(1):30–9.
doi: 10.1172/JCI69738 pubmed: 24382387 pmcid: 3871231
Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6(10):a026831.
doi: 10.1101/cshperspect.a026831 pubmed: 27599530 pmcid: 5046688
Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol. 2003;23(23):8563–75.
doi: 10.1128/MCB.23.23.8563-8575.2003 pubmed: 14612401 pmcid: 262657
Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, et al. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Mol Med. 2018;10(4):e8478.
doi: 10.15252/emmm.201708478 pubmed: 29523594 pmcid: 5887910
Han R, Nusbaum O, Chen X, Zhu Y. Valeric acid suppresses liver cancer development by acting as a novel HDAC inhibitor. Mol Ther Oncol. 2020;19:8–18.
doi: 10.1016/j.omto.2020.08.017
Fengqin S, Ya L, Rui H, et al. Valerian and valeric acid inhibit growth of breast cancer cells possibly by mediating epigenetic modifications. Sci Rep. 2021;11(2519):1–10.
Rui H, Hongxing Y, Lingeng L, et al. Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis. Sci Rep. 2021;11(1):8626–37.
doi: 10.1038/s41598-021-88133-7
Hernández P, Alem D, Nieves M, et al. Chemosensitizer effect of cisplatin-treated bladder cancer cells by phenazine-5,10-dioxides. Environ Toxicol Pharmacol. 2019;69:9–15.
doi: 10.1016/j.etap.2019.03.015 pubmed: 30921672
Ma L, Bian X, Lin W. Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. J Exp Clin Cancer Res. 2021;40(1):1–7.
doi: 10.1186/s13046-020-01805-6
Mayr C, Kiesslich T, Erber S, et al. HDAC screening identifies the HDAC Class I inhibitor romidepsin as a promising epigenetic drug for biliary tract cancer. Cancers (Basel). 2021;13(15):35.
doi: 10.3390/cancers13153862
Rui H, Xinyi C, Ya L, et al. MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3. Cancer Manage Res. 2019;11(5):2963–76.
Rui H, Jing Z, Lingeng L. MicroRNA-34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression[J]. Oncol Rep. 2020;43(6):2062–72.
Tan PY, Wen LJ, Li HN, et al. MiR-548c-3p inhibits the proliferation, migration and invasion of human breast cancer cell by targeting E2F3[J]. Cytotechnology. 2000;72(5):751–61.
doi: 10.1007/s10616-020-00418-3
Zheng Z, Bian Y, Zhang Y, et al. Metformin activates AMPK/SIRT1/NF-kappaB pathway and induces mitochondrial dysfunction to drive caspase3/GSDME-mediated cancer cell pyroptosis. Cell Cycl. 2020;19(10):1089–104.
doi: 10.1080/15384101.2020.1743911
Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, et al. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Mol Med. 2018. https://doi.org/10.15252/emmm.201708478 .
doi: 10.15252/emmm.201708478 pubmed: 29523594 pmcid: 5887910
Casas AI, Hassan AA, Larsen SJ, Gomez-Rangel V, Elbatreek M, Kleikers PWM, et al. From single drug targets to synergistic network pharmacology in ischemic stroke. Proc Natl Acad Sci USA. 2019;116(14):7129–36.
doi: 10.1073/pnas.1820799116 pubmed: 30894481 pmcid: 6452748
Feng YY. Significance, feasibility, and perspectives of networks pharmacology in treating cancer. TMR Cancer. 2018;1(4):105–10.
Zhang R, Zhu X, Bai H, Ning K. Network pharmacology databases for traditional Chinese medicine: review and assessment. Front Pharmacol. 2019;10:123.
doi: 10.3389/fphar.2019.00123 pubmed: 30846939 pmcid: 6393382

Auteurs

Rui Han (R)

Department of Chinese Medicine, Naval Medical University, Shanghai, 200433, People's Republic of China. dianxiqiao@foxmail.com.
Department of Chinese Medicine Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, 200433, People's Republic of China. dianxiqiao@foxmail.com.
Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, People's Republic of China. dianxiqiao@foxmail.com.
Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, 60 College Street, New Haven, CT, 06520-8034, USA. dianxiqiao@foxmail.com.
School of Medicine, Center for Biomedical Data Science, Yale University, 60 College Street, New Haven, CT, 06520-8034, USA. dianxiqiao@foxmail.com.
Yale Cancer Center, Yale University, 60 College Street, New Haven, CT, 06520-8034, USA. dianxiqiao@foxmail.com.
ORCID: 0000-0001-8856-3681

Hongxing Yang (H)

Beijing University of Traditional Chinese Medicine, Beijing, 100700, People's Republic of China.
Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, People's Republic of China.

Ya Li (Y)

Department of Integrated Chinese and Western Medicine & Geriatric Oncology, Peking University Cancer Hospital, Beijing, 100142, People's Republic of China.

Changquan Ling (C)

Department of Chinese Medicine, Naval Medical University, Shanghai, 200433, People's Republic of China.
Department of Chinese Medicine Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, 200433, People's Republic of China.

Lingeng Lu (L)

Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, 60 College Street, New Haven, CT, 06520-8034, USA. lingeng.lu@yale.edu.
School of Medicine, Center for Biomedical Data Science, Yale University, 60 College Street, New Haven, CT, 06520-8034, USA. lingeng.lu@yale.edu.
Yale Cancer Center, Yale University, 60 College Street, New Haven, CT, 06520-8034, USA. lingeng.lu@yale.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Valeric acid acts as a novel HDAC3 inhibitor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines régulatrices de l'apoptose › Caspases › Caspases effectrices › Caspase-3 › Valeric acid acts as a novel HDAC3 inhibitor...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de désacétylase d'histone › Valeric acid acts as a novel HDAC3 inhibitor...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Amidohydrolases › Histone deacetylases › Valeric acid acts as a novel HDAC3 inhibitor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Valeric acid acts as a novel HDAC3 inhibitor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Valeric acid acts as a novel HDAC3 inhibitor...
questionsmedicales.fr › Lipides › Acides gras › Acides gras volatils › Valérates › Acides pentanoïques › Valeric acid acts as a novel HDAC3 inhibitor...
questionsmedicales.fr › Tissus › Glandes exocrines › Prostate › Valeric acid acts as a novel HDAC3 inhibitor...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Valeric acid acts as a novel HDAC3 inhibitor...